Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Trial for Pediatric Nephrotic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
- Status
- WITHDRAWN
- Phase
- PHASE2
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Vasculitis Maintenance Study
- Status
- COMPLETED
- Phase
- PHASE3
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
- Status
- COMPLETED
- Phase
- PHASE2
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- N/A
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2